About: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $11.08 (-0.09%)
OCULNASDAQOcular Therapeutix Inc
Loading watchlist status…
Ocular Therapeutix Inc share price
OCUL price activity
Last Price
Change (24hr)
USD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
OCUL price performance
4,04%
5D
24,08%
1M
-8,73%
YTD
-8,66%
1Y
OCUL price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US-NASDAQ rank
N/ASector Rank
N/Aquote.marketSignals